Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vaxcyte (PCVX) Other financing activities (2020 - 2024)

Vaxcyte (PCVX) has 4 years of Other financing activities data on record, last reported at $9.3 million in Q3 2024.

  • On a quarterly basis, Other financing activities rose 258.39% to $9.3 million in Q3 2024 year-over-year; TTM through Sep 2024 was $20.6 million, a 481.75% increase, with the full-year FY2023 number at $3.9 million, up 350.17% from a year prior.
  • Other financing activities reached $9.3 million in Q3 2024 per PCVX's latest filing, up from $565000.0 in the prior quarter.
  • Over the last five years, Other financing activities for PCVX hit a ceiling of $9.3 million in Q3 2024 and a floor of -$3.4 million in Q4 2020.
  • A 4-year average of $2.1 million and a median of $794000.0 in 2022 define the central range for Other financing activities.
  • On a YoY basis, Other financing activities climbed as much as 354.75% in 2024 and fell as far as 164.02% in 2024.
  • Tracing PCVX's Other financing activities over 4 years: stood at -$3.4 million in 2020, then surged by 125.56% to $861000.0 in 2022, then skyrocketed by 762.02% to $7.4 million in 2023, then grew by 25.79% to $9.3 million in 2024.
  • Business Quant data shows Other financing activities for PCVX at $9.3 million in Q3 2024, $565000.0 in Q2 2024, and $3.3 million in Q1 2024.